BioPlus Acquisition Corp

BioPlus Acquisition Corp
BioPlus Acquisition Corp's leadership and board differentially consists of recognized industry leaders, including CEOs, CFOs, COOs, CSOs, Auditors, Investors, Bankers and experts covering all functional disciplines needed to maximize the value creation opportunity for a life sciences company. We bring over 200 years of collective experience in: 1) Identifying, developing and marketing value creating biotech assets, 2) Private and public company financing and dealmaking, 3) Audit and accounting, and 4) Advisory and board experience. We believe our team has demonstrated commitment to building valuable assets and can be leveraged as true long-term partners who can help maximize the value creation opportunity for a potential business combination.

Company Overview

Size
$230MM (over 5x oversubscribed)
IPO Date
December 2, 2021
Unit Structure
1 Share of Class A Common Stock and 1/2 Warrant
Duration
18 months to acquire target
Sector
Life Sciences

Objectives

Acquire Biotech Company Valued Above $1B

Provide Operational Guidance and Mentorship for Partner Management Team Post Combination as a Public Company

Live Stock Chart

Team

Ross Haghighat

CEO, CFO | BioPlus

Ross Haghighat

CEO, CFO | BioPlus

Jonathan Rigby

Chairman, CBO | BioPlus

Jonathan Rigby

Chairman, CBO | BioPlus

Ronald Eastman

Vice Chairman | BioPlus

Ronald Eastman

Vice Chairman | BioPlus

Stephen Sherwin, M.D.

Director | BioPlus

Stephen Sherwin, M.D.

Director | BioPlus

Lou Lange, M.D., Ph.D.

Director | BioPlus

Lou Lange, M.D., Ph.D.

Director | BioPlus

Glen Giovannetti

Director | BioPlus

Director | BioPlus

Glen Giovannetti

Director | BioPlus

Director | BioPlus

Shawn Cross

Director | BioPlus

Shawn Cross

Director | BioPlus

Recent News